AzTrials
AzTrials

DiabetesNCT00341237

Personalized Environment and Genes Study

An observational study of Diabetes and Heart Disease, run by National Institute of Environmental Health Sciences (NIEHS) at 2 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known to explain only 20% and 40% of the etiology of common disease. Read more about this study

Who is it for?
Ages 18 to 120 yearsHealthy volunteers can take part
Conditions the study is for
Diabetes, Heart Disease, Asthma
How many people
25,000 participants
Where
2 sitesUnited States
Study dates
26 May 2010to not given
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 120 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Convenience sample from the general population.

Who may be able to join

  • In order to be eligible for participation in this study, an individual must meet all of the following criteria:
  • Adults greater than or equal to 18 years of age
  • If female, must not be (self-reported as) pregnant. At the time of enrollment, a pregnancy test will only be done at the PI s discretion.
  • Able to understand and provide written informed consent
  • Able to come to the NIEHS Clinical Research Unit (CRU) for enrollment and study-related visits/procedures.

Who cannot join

  • An individual who does not meet the inclusion criteria listed above is excluded from participation in this study.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Jennifer L Emerson contact

(800) 860-3804

niehs-pegs-info@nih.gov

Lawrence S Kirschner, M.D. contact

(984) 287-3562

lawrence.kirschner@nih.gov

United States2 sites, 2 recruiting
  • University of North Carolina

    Chapel Hill, North Carolina, 27599-7030

    Bradford Powell, M.D., Not Listed, bradford.powell@unc.edu

    Recruiting
  • NIEHS Clinical Research Unit (CRU)

    Research Triangle Park, North Carolina, 27713

    Jennifer Emerson, 800-860-3804, jennifer.emerson@nih.gov

    Recruiting

Other trials in United States

About this study

Despite the overwhelming focus on genetic and genomic causes of human disease over the past two decades, it has been estimated that genetics is currently known to explain only 20% and 40% of the etiology of common disease. Thus, it is becoming increasingly apparent that human disease is a consequence of both genetic susceptibility and environmental exposures. Importantly, while individuals cannot change their genetic composition, we do have the ability both personally and as a society, to influence our environment, promoting health and decreasing the risk of disease. The Personalized Environment and Genes Study (PEGS) aims to determine how the environment and gene-environment interactions can inform our understanding of human health and disease. As science has evolved, so too has the science of this project. This evolution was reflected in a change in the title of this project from the Environmental Polymorphisms Registry (EPR) to the Personalized Environment and Genes Study (PEGS) to more accurately reflect the science that can be conducted. PEGS is a unique resource because of the depth of environmental phenotyping which includes extensive information from exposome surveys, as well as whole genome sequencing on a significant number of participants in the cohort. While it is small relative to genomic cohorts, none of these have the extensive environmental data that is present in PEGS. In addition, other cohorts with deep environmental data lack the depth of genomic data that is present in PEGS. Importantly, PEGS has already provided important analytic advances that are of great interest to and can be confirmed in larger cohorts such as All of Us.

The Personalized Environment and Genes Study (PEGS) aims to provide a resource for environmental health translational research by examining gene-environment interactions in health and disease. PEGS is an extension of two previous efforts where it began as a pilot study, the Environmental Polymorphisms Study (EPS; IRB# 02E9004) and was approved subsequently as a full protocol titled the Environmental Polymorphisms Registry (EPR) (IRB #04-E-N0053 and transitioned to its current ID# 04-E-0053). The EPR was envisioned as a phenotype-by-genotype registry of participants who had donated DNA samples, and who had agreed to be contacted for follow-up clinical translational studies based on their DNA genotypes. At the time, the only information available was a participant s age, sex, race, and ethnicity. Further phenotyping of a participant and/or any biospecimens obtained were investigated during a follow-up translational clinical study on participants recruited based on their genotype (hence phenotype-by-genotype) and the PEGS was the first recruit-by- genotype study at the NIH. Following a period focused on recruiting approximately 15,000 participants to enable genotyping of rare (approximately 1% minor allele frequency) single nucleotide polymorphisms (SNPs), the PEGS Consortium Project was undertaken in 2010- 2011 to examine, using the DNA of nearly 4,000 participants, approximately 700 SNPs in approximately 80 environmental response genes that work in concert with environmental exposures to elicit a phenotype. Several clinical follow-up studies, genotype-phenotype association studies, and publications have resulted from the PEGS Consortium Project.

Read more

To expand phenotype information available to researchers, the Health and Exposure Questionnaire was administered between 2013-2014. In 2017, a more detailed Exposome Questionnaire which includes questions relating to the external and internal exposome was administered. This was an important resource through which to integrate exposures with genotype-phenotype association studies.

Whole genome sequencing has now been performed on approximately 4700 participants who were reconsented for this purpose, as indicated above. Questionnaire data was fully adjudicated and combined in a robust and searchable database. With the increased power of the data available, the project was renamed as the Personalized Environment and Genes Study (PEGS) and rolled out in Sept. 2021.

Read the detailed description

Study Description: The Personalized Environment and Genes Study (PEGS) integrates genetic and environmental data to understand disease etiology, identify disease risk factors, and improve disease prevention.

Objectives: The objective of PEGS is to provide a resource for environmental health translational research by examining environment and gene-environment interactions in health and disease. PEGS will incorporate exposure and health information with or without genomic information to address the following objectives.

  • Primary Objective: To uncover novel environmental risk factors for the most prevalent health conditions and diseases.
  • Secondary Objective: To use an environmental precision medicine framework to uncover genetic susceptibilities to specific environmental exposures that can ultimately be used to provide a fuller understanding of individual risks for diseases.

Endpoints:

Primary Endpoints:

  1. Dichotomous phenotype (multiple analyses; each analysis is focused on a single dichotomous phenotype of clinical interest, or a group of mechanistically related dichotomous phenotypes) Example: asthma;
  2. Continuous phenotype (multiple analyses; each analysis is focused on a clinically relevant continuous phenotype). Example: FEV1, an indicator of asthma severity.

Secondary Endpoints:

  1. Phenome (simultaneous assessment of all clinically relevant phenotypes);
  2. Exposome.
Keywords
Genotype, Phenotype, Environmental Factor, Single Nucleotide Polymorphism, Natural History
Medical subject headings
Diabetes Mellitus, Heart Diseases, Asthma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00341237
Study groupRoleWhat they receive
polymorphismsSpecimens are available to investigators in coded form to anonymously screen for the presence of single-nucleotide polymorphisms (SNPs) and other mutations in DNA.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease

    Genetic changes and disease.

    Measured: End of study

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Jun 2006 (estimated)
  2. Study start26 May 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
25,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00341237
Sponsor's protocol ID
040053
Other IDs
04-E-0053
Status last verified
31 Jul 2026
First submitted
19 Jun 2006
Last updated
16 Sep 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: The types of data to be collected are clinical, demographics, medical history, questionnaires, laboratory, health records, and sequencing data. Digital data are collected and stored securely in REDCap, and biological specimens in monitored freezers. Raw data is extracted from REDCap, transformed and combined as needed, and stored in SAS, R, and csv datasets. De-identified data will be shared with IRB-approved researchers conducting genotyping, exposure, or disease-specific callback studies, and these data will be labeled only with PEGS PINs. Any new projects that meet the definition of Human Subjects Research (HSR) will require a separate IRB-approved protocol to receive PII. With participant consent, de identified whole genome or exome data will be submitted to NIH designated repositories such as dbGaP. Follow up studies are separate from PEGS and require scientific, IRB, and PEGS committee review before any personal information is released.

Publications

  • Mack JA, Burkholder A, Akhtari FS, House JS, Sovio U, Smith GCS, Schmitt CP, Fargo DC, Hall JE, Motsinger-Reif AA. A multi-ancestry genome-wide association study identifies novel candidate loci in the RARB gene associated with hypertensive disorders of pregnancy. HGG Adv. 2025 Jan 9;6(1):100385. doi: 10.1016/j.xhgg.2024.100385. Epub 2024 Nov 22.

    PubMed 39580622
  • Hussain S, Johnson CG, Sciurba J, Meng X, Stober VP, Liu C, Cyphert-Daly JM, Bulek K, Qian W, Solis A, Sakamachi Y, Trempus CS, Aloor JJ, Gowdy KM, Foster WM, Hollingsworth JW, Tighe RM, Li X, Fessler MB, Garantziotis S. TLR5 participates in the TLR4 receptor complex and promotes MyD88-dependent signaling in environmental lung injury. Elife. 2020 Jan 28;9:e50458. doi: 10.7554/eLife.50458.

    PubMed 31989925

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes and Heart Disease, run by National Institute of Environmental Health Sciences (NIEHS) at 2 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jennifer L Emerson ((800) 860-3804, niehs-pegs-info@nih.gov), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disease (time frame: End of study). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00341237, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026; AzTrials last refreshed its copy on 29 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in